IMMU-132-11: A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

About this Study

The main purpose of this study is to determine whether treatment with the study drug, sacituzumab govitecan improves tumor shrinkage in participants with metastatic solid tumors. In addition, the study will determine how long tumor shrinkage lasts in participants after treatment with the study drug.  

Sponsor Protocol ID:IMMU-132-11
IRB Number:2019-0247
Actively Enrolling
Interventional
Phase 2
December 30, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria1. Female or male subjects, >18 years of age, able to understand and give written informed consent.

2. Subjects must have at least a 3-month life expectancy

3. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

4. Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 3 months after the last dose of study therapy. 

Exclusion Criteria1. Women who are pregnant or lactating.

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute
University Hospital
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Ruckdeschel, John C, M.D.
How to participate in our Clinical Trials